Dashboard › Demo Universe › Halcyon Medical Devices
Halcyon Medical Devices · HLCN
DEMO DATAUNDERWRITING ASSUMPTIONHOLDFinancial statements DEMO DATA ANALYST PROJECTION
| $M | FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.3B | $1.4B | $1.2B | $1.1B | $1.1B | $1.1B | $1.2B |
| % growth | 6.8% | 5.6% | 5.3% | -12.6% | -7.0% | -1.4% | 1.0% | 2.0% | |
| Direct costs / COGS | $407.1M | $428.4M | $445.5M | $476.0M | $460.1M | $441.5M | $428.6M | $426.1M | $427.7M |
| Gross profit (NOI for real estate) | $772.9M | $831.6M | $884.5M | $924.0M | $763.5M | $696.4M | $693.4M | $707.1M | $728.2M |
| % margin | 65.5% | 66.0% | 66.5% | 66.0% | 62.4% | 61.2% | 61.8% | 62.4% | 63.0% |
| Operating expenses (cash, adjusted) | $495.6M | $529.2M | $558.6M | $588.0M | $513.9M | $477.9M | $471.2M | $476.0M | $485.5M |
| EBITDA (company-adjusted basis) | $277.3M | $302.4M | $325.8M | $336.0M | $249.6M | $218.5M | $222.2M | $231.2M | $242.7M |
| % margin | 23.5% | 24.0% | 24.5% | 24.0% | 20.4% | 19.2% | 19.8% | 20.4% | 21.0% |
| D&A | $53.1M | $56.7M | $59.8M | $63.0M | $55.1M | $51.2M | $50.5M | $51.0M | $52.0M |
| Share-based compensation | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| EBIT | $224.2M | $245.7M | $266.0M | $273.0M | $194.6M | $167.3M | $171.7M | $180.2M | $190.7M |
| Interest expense | $50.2M | $53.2M | $56.1M | $59.1M | $71.1M | $69.7M | $68.3M | $67.9M | $29.5M |
| EBT | $174.0M | $192.5M | $209.9M | $213.9M | $123.5M | $97.6M | $103.4M | $112.3M | $161.2M |
| Taxes | $43.5M | $48.1M | $52.5M | $53.5M | $30.9M | $24.4M | $25.8M | $28.1M | $40.3M |
| Net income (model basis) | $130.5M | $144.4M | $157.4M | $160.4M | $92.6M | $73.2M | $77.5M | $84.2M | $120.9M |
| Capex | $47.2M | $50.4M | $53.2M | $56.0M | $39.2M | $36.4M | $35.9M | $36.3M | $37.0M |
| Working capital & other cash items | $6.7M | $9.6M | $8.4M | $8.4M | ($13.8M) | ($3.5M) | $4.8M | $8.1M | $9.7M |
| Free cash flow | $129.6M | $141.1M | $155.6M | $159.0M | $122.3M | $91.4M | $87.3M | $90.8M | $126.3M |
Historical columns are fictional demo inputs. Projections flow from the selected scenario’s assumptions (Scenarios tab): interest accrues on beginning balances by tranche; floating tranches use MAX(SOFR, floor) + spread + scenario shock; PIK accrues to principal. FCF = net income + D&A + SBC + PIK − capex − ΔNWC / other. Impairments, restructuring and other one-offs are excluded from EBITDA and net income and sit in the cash plug.
Sources & data lineage (3)
| Source | Document | Data type | Period | Accession | Doc date | Retrieved | Class |
|---|---|---|---|---|---|---|---|
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative financial statements FY2022–FY2025 | Income statement / cash flow | FY2022–FY2025 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Halcyon Medical Devices — illustrative capital structure & covenants | Debt schedule | As of 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Illustrative indicative bid marks (% of par) | Market price | 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |